Arthropathy occurrence under vedolizumab treatment for ulcerative colitis: four cases report and literature review
10.3760/cma.j.cn101480-20221210-00202
- VernacularTitle:溃疡性结肠炎患者使用维得利珠单克隆抗体后新发关节病四例报道并文献复习
- Author:
Lili SHANG
1
;
Kaituo HUANG
;
Lingya YAO
;
Qian CAO
Author Information
1. 浙江大学医学院附属邵逸夫医院消化内科，杭州 310016
- Publication Type:Journal Article
- Keywords:
Ulcerative colitis;
Vedolizumab;
Arthropathy;
Arthritis
- From:
Chinese Journal of Inflammatory Bowel Diseases
2023;07(4):335-337
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To summarize the clinical characteristics of patients with ulcerative colitis (UC) who developed joint manifestations after receiving vedolizumab (VDZ) .Methods:Patients with UC who developed joint manifestations after receiving VDZ at Sir Run Run Shaw Hospital, Zhejiang University School of Medicine from November 2020 to October 2021 were retrospectively included. Cases previously reported in the literature were revieved.Results:Four patients with UC were included, none of whom had extraintestinal manifestations previously. After receiving VDZ, four patients developed joint pain, and three had polyarticular involvement. Three patients had elevated C-reactive protein (CRP) and ultrasonography indicated joint effusion. No one discontinued due to the worsening of arthropathy and the joint manifestations all improved after treatment.Conclusion:Arthropathy may be induced after receiving VDZ, manifesting as elevated CRP, joint effusion, and bone marrow edema. After treatment with nonsteroidal anti-inflammatory drugs, glucocorticoids, immunosuppressants, or biological agents, most of the patients had a favorable prognosis.
